This funding opportunity supports research on novel or repurposed therapeutic agents for adult glioblastoma that can cross the blood brain barrier. It funds collaborative teams to drive agents from late pre-clinical development through early Phase 0/1 clinical trials, aiming to improve GBM treatment and enable seamless transition to later stage clinical trials.
Eligible applicants include U.S. state, county, city, and tribal governments, public and private higher education institutions, nonprofits, for-profit organizations, and small businesses. Foreign organizations and foreign components are not eligible.
